Background Patent foramen ovale (PFO) is a vestigial congenital cardiovascular structure
present in around 25% of adults. In most cases, PFO is entirely benign and requires no …

Background: There is a plethora of real-world data on the safety and effectiveness of direct-
acting oral anticoagulants (DOACs); however, study heterogeneity has contributed to …

Background: Although non-vitamin K antagonist oral anticoagulants (NOACs) are
recommended over vitamin K antagonists (VKAs) in atrial fibrillation (AF) management …

Introduction Amongst the 25.7 million survivors and 6.5 million deaths from stroke between
1990 and 2013, ischemic strokes accounted for approximately 70% and 50% of the cases …

Objectives To assess the risk of stroke/systemic embolism (SE) and major bleeding
associated with the use of oral anticoagulants in elderly patients with atrial fibrillation (AF) in …

To compare the efficacy and safety of apixaban and rivaroxaban for the prevention of stroke
in patients with nonvalvular atrial fibrillation (NVAF) by way of a meta-analysis informed by …

Importance Spontaneous (nontraumatic) intracerebral hemorrhage (ICH) is the most severe
complication of antithrombotic drug use. Objectives To estimate the strength of association …

Background Anticoagulants are widely used but can lead to iatrogenic events such as
bleeding. Limited data exists regarding the characteristics and management of patients …

Background: Atrial fibrillation (AF) is the leading cause of ischemic stroke and treatment has
focused on reducing this risk through anticoagulation. Direct Oral Anticoagulants (DOACs) …

Objective To compare real-world effectiveness and safety of direct oral anticoagulants
(DOACs) in patients with nonvalvular atrial fibrillation (AFib) for prevention of stroke. Study …